Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2021; 9(26): 7845-7849
Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7845
Chronic active Epstein-Barr virus infection treated with PEG-aspargase: A case report
De-Li Song, Jing-Shi Wang, Lei-Lei Chen, Zhao Wang
De-Li Song, Jing-Shi Wang, Lei-Lei Chen, Zhao Wang, Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Author contributions: Song DL and Chen LL took care of the patient; Song DL wrote this article; Wang JS and Wang Z guided article writing; all authors have read and approved the final version for submission.
Supported by National Natural Science Foundation of China, No. 81871633; Beijing Natural Science Foundation, No. 7181003; and Beijing Municipal Administration of Hospitals’ Ascent Plan, No. DFL20180101.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhao Wang, MD, Professor, Department of Hematology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing 100050, China. wangzhao@ccmu.edu.cn
Received: March 29, 2021
Peer-review started: March 29, 2021
First decision: April 28, 2021
Revised: May 8, 2021
Accepted: August 13, 2021
Article in press: August 13, 2021
Published online: September 16, 2021
Processing time: 165 Days and 2.6 Hours
Core Tip

Core Tip: Chronic active Epstein-Barr virus (EBV) infection may lead to fatal diseases, including EBV-positive lymphoproliferative disorders, lymphomas, and hemophagocytic lymphohistiocytosis. We present a chronic active EBV (CAEBV) patient who was treated with PEG-aspargase and achieved decreased load of EBV-DNA. PEG-aspargase requires further investigation as a chemotherapy drug for CAEBV to reduce the load of EBV-DNA.